{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-uk-cta-notifications-via-national-systems-post-brexit”
},
“headline”: “SOP for UK CTA/Notifications via National Systems (Post-Brexit)”,
“description”: “This SOP describes the procedures for submitting Clinical Trial Authorisations (CTAs) and notifications to the MHRA via UK national systems in the post-Brexit regulatory environment. It ensures compliance with UK-specific requirements for clinical trial approval and oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for UK CTA/Notifications via National Systems (Post-Brexit)

Purpose

The purpose of this SOP is to define the process for submitting Clinical Trial Authorisations (CTAs) and related notifications to the Medicines and Healthcare products Regulatory Agency (MHRA) via UK national systems, in accordance with post-Brexit regulatory requirements. This ensures that trials conducted in the UK comply with local legislation, independent of EU systems.

Scope

This SOP applies to sponsors, CROs, regulatory affairs, investigators, and QA staff involved in clinical trials in the United Kingdom. It covers initial CTA submission, substantial amendments, end-of-trial notifications, and other regulatory communications required under MHRA guidance.

Responsibilities

• Sponsor: Prepares and submits CTA applications, amendments, and notifications via the MHRA national system.
• CRO: Supports preparation of submissions and monitors MHRA communications.
• Investigator: Provides essential site and investigator information required for CTA approval.
• Regulatory Affairs: Coordinates submissions, tracks timelines, and ensures compliance with MHRA requirements.
• QA: Audits submissions and maintains TMF documentation of all regulatory interactions.

Accountability

The Sponsor’s Regulatory Affairs Head is accountable for ensuring that all UK CTA submissions and notifications comply with MHRA requirements in the post-Brexit environment.

Procedure

1. CTA Preparation and Submission
1.1 Compile CTA application including protocol, Investigator’s Brochure, IMPD, and supporting documents.
1.2 Submit via the MHRA national system (e.g., Combined Review Service).
1.3 Document in CTA Submission Log (Annexure-1).

2. CTA Acknowledgment and Queries
2.1 Monitor MHRA portal for acknowledgment and requests for information.
2.2 Respond to MHRA queries within specified timelines.
2.3 Record in CTA Query Response Log (Annexure-2).

3. Substantial Amendments
3.1 Submit amendments to MHRA via the national system.
3.2 Track approval timelines.
3.3 Document in Amendment Submission Log (Annexure-3).

4. End-of-Trial Notifications
4.1 Submit end-of-trial notification within 90 days of trial conclusion.
4.2 For early termination, submit within 15 days.
4.3 Record in End-of-Trial Notification Log (Annexure-4).

5. Archiving and Documentation
5.1 File all submission documents, approvals, and communications in TMF.
5.2 Maintain inspection readiness.
5.3 Record in Archiving Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• CTA: Clinical Trial Authorisation
• MHRA: Medicines and Healthcare products Regulatory Agency
• CRO: Contract Research Organization
• QA: Quality Assurance
• IMPD: Investigational Medicinal Product Dossier
• TMF: Trial Master File

Documents

1. CTA Submission Log (Annexure-1)
2. CTA Query Response Log (Annexure-2)
3. Amendment Submission Log (Annexure-3)
4. End-of-Trial Notification Log (Annexure-4)
5. Archiving Log (Annexure-5)

References

• MHRA Guidance – Clinical Trial Applications in the UK
• MHRA Official Website
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: CTA Submission Log

Annexure-2: CTA Query Response Log

Annexure-3: Amendment Submission Log

Annexure-4: End-of-Trial Notification Log

Annexure-5: Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-susar-sae-reporting-to-uk-authority-country-specific-pathways”
},
“headline”: “SOP for SUSAR/SAE Reporting to UK Authority (Country-Specific Pathways)”,
“description”: “This SOP outlines the procedures for reporting Suspected Unexpected Serious Adverse Reactions (SUSARs) and Serious Adverse Events (SAEs) to the MHRA in compliance with UK country-specific requirements. It ensures timely reporting, regulatory compliance, and subject safety monitoring.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for SUSAR/SAE Reporting to UK Authority (Country-Specific Pathways)

Purpose

The purpose of this SOP is to describe the process for reporting Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) to the Medicines and Healthcare products Regulatory Agency (MHRA) in accordance with UK country-specific requirements. This ensures patient safety, compliance with Good Clinical Practice (GCP), and adherence to expedited reporting timelines.

Scope

This SOP applies to sponsors, CROs, investigators, pharmacovigilance (PV) staff, and regulatory affairs teams responsible for safety data management in clinical trials conducted in the UK. It covers SAE documentation, SUSAR detection, expedited reporting, and submission through MHRA electronic pathways.

Responsibilities

• Sponsor: Ensures SUSAR and SAE reports are submitted to MHRA within required timelines.
• CRO: Supports safety data collection, SAE follow-up, and submissions to MHRA.
• Investigator: Identifies, documents, and reports SAEs/SUSARs promptly to the sponsor.
• PV Department: Prepares, validates, and submits electronic safety reports to MHRA.
• QA: Audits safety reporting processes for UK regulatory compliance.

Accountability

The Sponsor’s Head of Pharmacovigilance is accountable for ensuring all SAE and SUSAR reporting complies with MHRA requirements and UK-specific timelines.

Procedure

1. SAE Reporting
1.1 Investigators must record all SAEs in source documents and CRFs.
1.2 SAEs must be reported to the sponsor within 24 hours of awareness.
1.3 Record in SAE Reporting Log (Annexure-1).

2. SUSAR Identification
2.1 PV team evaluates reported SAEs to determine causality and expectedness.
2.2 Confirmed SUSARs must be prepared for expedited reporting.
2.3 Record in SUSAR Identification Log (Annexure-2).

3. Reporting to MHRA
3.1 Submit SUSARs electronically to MHRA via EudraVigilance MHRA Gateway or national system.
3.2 Fatal or life-threatening SUSARs: report within 7 days (follow-up within 8 additional days).
3.3 All other SUSARs: report within 15 days.
3.4 Document in MHRA Reporting Log (Annexure-3).

4. Communication with Ethics Committees
4.1 SUSARs must also be submitted to UK Research Ethics Committees as required.
4.2 Record submissions in EC Reporting Log (Annexure-4).

5. Archiving
5.1 File all SAE/SUSAR documentation and MHRA submissions in the TMF.
5.2 Record archiving in Safety Archiving Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• MHRA: Medicines and Healthcare products Regulatory Agency
• PV: Pharmacovigilance
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• EC: Ethics Committee
• CRF: Case Report Form

Documents

1. SAE Reporting Log (Annexure-1)
2. SUSAR Identification Log (Annexure-2)
3. MHRA Reporting Log (Annexure-3)
4. EC Reporting Log (Annexure-4)
5. Safety Archiving Log (Annexure-5)

References

• MHRA Guidance – Safety Reporting in Clinical Trials
• ICH GCP Guidelines
• UK Guidance on Pharmacovigilance

Version: 1.0

Approval Section

Annexures

Annexure-1: SAE Reporting Log

Annexure-2: SUSAR Identification Log

Annexure-3: MHRA Reporting Log

Annexure-4: EC Reporting Log

Annexure-5: Safety Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-uk-gdpr-compliance-uk-gdpr-dpa-in-trials”
},
“headline”: “SOP for UK GDPR Compliance (UK-GDPR, DPA) in Trials”,
“description”: “This SOP defines standardized processes for ensuring compliance with UK General Data Protection Regulation (UK-GDPR) and the Data Protection Act (DPA) 2018 in clinical trials. It outlines subject data rights, sponsor responsibilities, and secure data management practices for research conducted in the UK.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for UK GDPR Compliance (UK-GDPR, DPA) in Trials

Purpose

The purpose of this SOP is to establish standardized procedures to ensure clinical trials in the United Kingdom comply with the UK General Data Protection Regulation (UK-GDPR) and the Data Protection Act (DPA) 2018. It ensures lawful processing of personal data, protection of subject privacy, and secure handling of trial-related records.

Scope

This SOP applies to sponsors, investigators, CROs, data management teams, and QA staff responsible for managing subject personal data in clinical trials conducted in the UK. It covers subject data collection, processing, transfer, retention, rights management, and breach reporting.

Responsibilities

• Sponsor: Acts as Data Controller, defines lawful basis for processing, and ensures compliance with UK-GDPR/DPA 2018.
• CRO: Operates as Data Processor under contractual agreement, implements GDPR-compliant procedures.
• Investigator: Ensures informed consent covers data protection and subject rights.
• Data Protection Officer (DPO): Oversees compliance with GDPR/DPA requirements, manages subject requests.
• QA: Audits data handling and archiving for compliance.

Accountability

The Sponsor’s Data Protection Officer (DPO) is accountable for ensuring GDPR/DPA compliance throughout the lifecycle of clinical trial data management.

Procedure

1. Lawful Basis for Processing
1.1 Define lawful basis for processing subject data (e.g., informed consent, public interest, legal obligations).
1.2 Document in GDPR Compliance Log (Annexure-1).

2. Subject Rights Management
2.1 Provide subjects with GDPR-compliant privacy notices.
2.2 Implement processes for handling subject rights requests (access, rectification, erasure, restriction).
2.3 Record requests in Subject Rights Log (Annexure-2).

3. Data Minimization and Pseudonymization
3.1 Collect only essential data required for trial objectives.
3.2 Apply pseudonymization or anonymization where applicable.
3.3 Document in Data Minimization Log (Annexure-3).

4. Cross-Border Data Transfers
4.1 Ensure compliance with UK adequacy decisions and transfer mechanisms.
4.2 Document in Cross-Border Data Transfer Log (Annexure-4).

5. Data Breach Reporting
5.1 Implement internal reporting procedures for suspected breaches.
5.2 Notify the ICO (Information Commissioner’s Office) within 72 hours, if required.
5.3 Record breaches in Data Breach Log (Annexure-5).

6. Archiving and Retention
6.1 Archive subject data securely in compliance with retention periods.
6.2 Document in Archiving Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• GDPR: General Data Protection Regulation
• UK-GDPR: United Kingdom General Data Protection Regulation
• DPA: Data Protection Act 2018
• DPO: Data Protection Officer
• CRO: Contract Research Organization
• QA: Quality Assurance
• ICO: Information Commissioner’s Office

Documents

1. GDPR Compliance Log (Annexure-1)
2. Subject Rights Log (Annexure-2)
3. Data Minimization Log (Annexure-3)
4. Cross-Border Data Transfer Log (Annexure-4)
5. Data Breach Log (Annexure-5)
6. Archiving Log (Annexure-6)

References

• ICO – UK GDPR Guidance
• UK Data Protection Act 2018
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: GDPR Compliance Log

Annexure-2: Subject Rights Log

Annexure-3: Data Minimization Log

Annexure-4: Cross-Border Data Transfer Log

Annexure-5: Data Breach Log

Annexure-6: Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-hra-rec-interface-and-uk-site-approvals”
},
“headline”: “SOP for HRA/REC Interface and UK Site Approvals”,
“description”: “This SOP describes the procedures for managing submissions, communications, and approvals with the Health Research Authority (HRA) and Research Ethics Committees (RECs) in the United Kingdom. It ensures compliance with UK-specific requirements for site approvals and trial conduct.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for HRA/REC Interface and UK Site Approvals

Purpose

The purpose of this SOP is to establish procedures for submitting, tracking, and managing clinical trial applications and communications with the Health Research Authority (HRA) and Research Ethics Committees (RECs) in the United Kingdom. It ensures that site approvals are obtained and maintained in accordance with UK-specific regulations and Good Clinical Practice (GCP).

Scope

This SOP applies to sponsors, CROs, investigators, and regulatory affairs staff involved in submissions to HRA and RECs for trial approvals. It covers initial submissions, REC communications, site-specific assessments (SSA), and documentation of approvals in the Trial Master File (TMF).

Responsibilities

• Sponsor: Oversees all REC/HRA submissions and ensures compliance with approval timelines.
• CRO: Supports preparation and submission of IRAS applications to HRA/RECs.
• Investigator: Provides site-level documents for REC review and site approval.
• Regulatory Affairs: Manages REC communications and maintains regulatory documentation.
• QA: Verifies compliance of HRA/REC submissions and approvals with UK regulations.

Accountability

The Sponsor’s Regulatory Affairs Head is accountable for ensuring timely and complete HRA/REC approvals for UK clinical trial sites.

Procedure

1. Preparation of Submissions
1.1 Complete Integrated Research Application System (IRAS) forms for initial application.
1.2 Attach trial protocol, informed consent forms, Investigator’s Brochure, and other required documents.
1.3 Record in HRA/REC Submission Log (Annexure-1).

2. REC Review and Communication
2.1 Track communications from REC and respond to requests for information promptly.
2.2 Record discussions and clarifications in REC Communication Log (Annexure-2).

3. Site-Specific Assessments (SSA)
3.1 Submit site-specific documents for approval (PI CV, facilities checklist, insurance).
3.2 Record in SSA Approval Log (Annexure-3).

4. Approval and Documentation
4.1 File approval letters in TMF and ISF.
4.2 Communicate approvals to site staff prior to initiation.
4.3 Record in Approval Documentation Log (Annexure-4).

5. Ongoing Compliance
5.1 Maintain records of continuing approvals and renewals.
5.2 Record updates in Continuing Review Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• HRA: Health Research Authority
• REC: Research Ethics Committee
• IRAS: Integrated Research Application System
• SSA: Site-Specific Assessment
• TMF: Trial Master File
• ISF: Investigator Site File
• CRO: Contract Research Organization
• QA: Quality Assurance

Documents

1. HRA/REC Submission Log (Annexure-1)
2. REC Communication Log (Annexure-2)
3. SSA Approval Log (Annexure-3)
4. Approval Documentation Log (Annexure-4)
5. Continuing Review Log (Annexure-5)

References

• HRA Guidance – Approvals and Amendments
• Research Ethics Committees (RECs) Overview
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: HRA/REC Submission Log

Annexure-2: REC Communication Log

Annexure-3: SSA Approval Log

Annexure-4: Approval Documentation Log

Annexure-5: Continuing Review Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-uk-specific-archiving-and-retention-conditions”
},
“headline”: “SOP for UK-Specific Archiving and Retention Conditions”,
“description”: “This SOP provides detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with MHRA and GCP requirements, addressing both paper and electronic records, environmental controls, access restrictions, and timelines specific to UK regulations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for UK-Specific Archiving and Retention Conditions

Purpose

The purpose of this SOP is to define the requirements and detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with the Medicines and Healthcare products Regulatory Agency (MHRA), UK-GCP, and Data Protection Act (DPA 2018), with emphasis on maintaining data integrity, subject confidentiality, and readiness for regulatory inspection. This SOP also aligns with ICH E6(R2) and reflects UK-specific post-Brexit obligations for record retention.

Scope

This SOP applies to sponsors, CROs, investigators, archivists, data managers, IT administrators, and QA personnel involved in managing trial records. It covers both electronic and paper documents, including Trial Master File (TMF), Investigator Site File (ISF), source documents, informed consent forms, pharmacovigilance records, investigational product documentation, and all data required for MHRA inspection and global regulatory submissions. It also includes guidance on environmental controls for storage facilities, electronic archiving security, and destruction protocols specific to the UK.

Responsibilities

• Sponsor: Ensures long-term archiving of trial documents and sets retention timelines according to MHRA guidance.
• CRO: Implements sponsor-defined archiving processes and provides evidence of compliance.
• Investigator: Retains site-specific essential documents until sponsor confirmation of archive release.
• QA: Audits archiving and retention practices, ensuring facilities and procedures meet MHRA standards.
• IT/Archivist: Maintains secure electronic archives with validated systems, access controls, and disaster recovery plans.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring that trial records are archived and retained in compliance with MHRA requirements and are accessible for inspection at any time during the mandated retention period.

Procedure

1. Identification of Records for Archiving
1.1 Compile a list of essential documents per ICH GCP Section 8, including TMF, ISF, monitoring visit reports, CRFs, source documents, and safety reports.
1.2 Ensure all records are complete, signed, and dated before transfer to archives.
1.3 Prepare an Archiving Checklist (Annexure-1) to confirm completeness.

2. Retention Timelines (UK Specific)
2.1 Retain trial records for a minimum of 25 years or longer as required by MHRA.
2.2 Retain informed consent forms and subject data in accordance with UK-GDPR and DPA 2018 obligations.
2.3 For pediatric and gene therapy trials, retain records for the subject’s lifetime plus defined regulatory years, as required.
2.4 Record retention decisions in Retention Log (Annexure-2).

3. Storage and Environmental Controls
3.1 Store paper records in fireproof, pest-controlled, temperature- and humidity-monitored facilities.
3.2 Validate electronic archives with audit trails, encryption, and access logs.
3.3 Ensure offsite backup storage is available for redundancy.
3.4 Maintain an Environmental Monitoring Log (Annexure-3).

4. Security and Access Controls
4.1 Limit archive access to authorized personnel only.
4.2 Implement dual authentication for electronic archive access.
4.3 Maintain Archive Access Log (Annexure-4).

5. Document Transfer and Archival Process
5.1 Prepare Transfer Forms with document inventory and unique identifiers.
5.2 Investigator transfers ISF documents to sponsor only after closeout confirmation.
5.3 Sponsor confirms receipt and logs in Archival Receipt Log (Annexure-5).
5.4 Archive all correspondence, approvals, reports, and raw data relevant to UK submissions.

6. Electronic Archiving Validation
6.1 Validate e-archive systems per MHRA and FDA 21 CFR Part 11 equivalence.
6.2 Ensure system provides secure access, version control, and unalterable audit trails.
6.3 Conduct periodic system validation checks and document in e-Archive Validation Log (Annexure-6).

7. Inspection Readiness
7.1 Archive must be inspection-ready, with quick retrieval of documents.
7.2 Perform quarterly mock retrievals and document in Inspection Readiness Log (Annexure-7).

8. Record Destruction
8.1 Records may only be destroyed after expiration of MHRA-mandated retention timelines and sponsor authorization.
8.2 Use certified destruction services with documented proof of destruction.
8.3 Document in Record Destruction Log (Annexure-8).

9. Cross-Border Considerations
9.1 If documents are shared with non-UK authorities, ensure compliance with UK-GDPR transfer mechanisms.
9.2 Maintain logs of all cross-border transfers in Regulatory Transfer Log (Annexure-9).

10. Training and Oversight
10.1 All staff handling archiving must undergo training in MHRA and GCP-specific requirements.
10.2 Maintain training records in Training Log (Annexure-10).

Abbreviations

• SOP: Standard Operating Procedure
• MHRA: Medicines and Healthcare products Regulatory Agency
• TMF: Trial Master File
• ISF: Investigator Site File
• QA: Quality Assurance
• eTMF: Electronic Trial Master File
• DPA: Data Protection Act 2018
• UK-GDPR: UK General Data Protection Regulation

Documents

1. Archiving Checklist (Annexure-1)
2. Retention Log (Annexure-2)
3. Environmental Monitoring Log (Annexure-3)
4. Archive Access Log (Annexure-4)
5. Archival Receipt Log (Annexure-5)
6. e-Archive Validation Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)
8. Record Destruction Log (Annexure-8)
9. Regulatory Transfer Log (Annexure-9)
10. Training Log (Annexure-10)

References

• MHRA Guidance – Managing Clinical Trial Authorisations
• ICH GCP Guidelines
• UK Data Protection Act 2018

Version: 1.0

Approval Section

Annexures

Annexure-1: Archiving Checklist

Annexure-2: Retention Log

Annexure-3: Environmental Monitoring Log

Annexure-4: Archive Access Log

Annexure-5: Archival Receipt Log

Annexure-6: e-Archive Validation Log

Annexure-7: Inspection Readiness Log

Annexure-8: Record Destruction Log

Annexure-9: Regulatory Transfer Log

Annexure-10: Training Log

Revision History

For more SOPs visit: Pharma SOP